Department of Radiology, Shanxi Province Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, China.
GE Healthcare China, Shanghai, China.
Eur Radiol. 2019 Mar;29(3):1211-1220. doi: 10.1007/s00330-018-5683-9. Epub 2018 Aug 20.
To develop and validate a radiomics predictive model based on pre-treatment multiparameter magnetic resonance imaging (MRI) features and clinical features to predict a pathological complete response (pCR) in patients with locally advanced rectal cancer (LARC) after receiving neoadjuvant chemoradiotherapy (CRT).
One hundred and eighty-six consecutive patients with LARC (training dataset, n = 131; validation dataset, n = 55) were enrolled in our retrospective study. A total of 1,188 imaging features were extracted from pre-CRT T2-weighted (T2-w), contrast-enhanced T1-weighted (cT1-w) and ADC images for each patient. Three steps including least absolute shrinkage and selection operator (LASSO) regression were performed to select key features and build a radiomics signature. Combining clinical risk factors, a radiomics nomogram was constructed. The predictive performance was evaluated by receiver operator characteristic (ROC) curve analysis, and then assessed with respect to its calibration, discrimination and clinical usefulness.
Thirty-one of 186 patients (16.7%) achieved pCR. The radiomics signature derived from joint T2-w, ADC, and cT1-w images, comprising 12 selected features, was significantly associated with pCR status and showed better predictive performance than signatures derived from either of them alone in both datasets. The radiomics nomogram, incorporating the radiomics signature and MR-reported T-stages, also showed good discrimination, with areas under the ROC curves (AUCs) of 0.948 (95% CI, 0.907-0.989) and 0.966 (95% CI, 0.924-1.000), as well as good calibration in both datasets. Decision curve analysis confirmed its clinical usefulness.
This study demonstrated that the pre-treatment radiomics nomogram can predict pCR in patients with LARC and potentially guide treatments to select patients for a "wait-and-see" policy.
• Radiomics analysis of pre-CRT multiparameter MR images could predict pCR in patients with LARC. • Proposed radiomics signature from joint T2-w, ADC and cT1-w images showed better predictive performance than individual signatures. • Most of the clinical characteristics were unable to predict pCR.
基于治疗前多参数磁共振成像(MRI)特征和临床特征,开发和验证一种放射组学预测模型,以预测接受新辅助放化疗(CRT)的局部晚期直肠癌(LARC)患者的病理完全缓解(pCR)。
我们的回顾性研究纳入了 186 例连续的 LARC 患者(训练数据集,n=131;验证数据集,n=55)。为每位患者从治疗前 T2 加权(T2-w)、对比增强 T1 加权(cT1-w)和 ADC 图像中提取了 1188 个影像学特征。通过最小绝对值收缩和选择算子(LASSO)回归进行了三个步骤,以选择关键特征并构建放射组学特征。结合临床危险因素,构建了放射组学列线图。通过受试者工作特征(ROC)曲线分析评估预测性能,然后根据其校准、判别和临床实用性进行评估。
186 例患者中有 31 例(16.7%)达到 pCR。来自联合 T2-w、ADC 和 cT1-w 图像的放射组学特征,包含 12 个选定特征,与 pCR 状态显著相关,并且在两个数据集的单独特征中,预测性能更好。纳入放射组学特征和 MRI 报告 T 分期的放射组学列线图也表现出良好的判别能力,ROC 曲线下面积(AUC)分别为 0.948(95%CI,0.907-0.989)和 0.966(95%CI,0.924-1.000),并且在两个数据集均具有良好的校准能力。决策曲线分析证实了其临床实用性。
本研究表明,治疗前放射组学列线图可预测 LARC 患者的 pCR,并可能指导治疗以选择患者进行“等待观察”策略。
治疗前多参数 MRI 图像的放射组学分析可预测 LARC 患者的 pCR。
来自联合 T2-w、ADC 和 cT1-w 图像的建议放射组学特征比单个特征具有更好的预测性能。
大多数临床特征无法预测 pCR。